Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
Open Access
- 13 October 2009
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 101 (9), 1565-1573
- https://doi.org/10.1038/sj.bjc.6605247
Abstract
Background: Methods: Results: Conclusion:This publication has 20 references indexed in Scilit:
- Vascular‐targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light dosesBJU International, 2008
- Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic TherapyClinical Cancer Research, 2008
- Randomized Multicenter Trial of More Intense and Standard Early Verteporfin Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- Photodynamic therapy for neovascular age-related macular degenerationCochrane Database of Systematic Reviews, 2007
- Photodynamic therapy and cancer: a brief sightseeing tourExpert Opinion on Drug Delivery, 2007
- Magnetic resonance imaging correlated with the histopathological effect of Pd‐bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate glandLasers in Surgery and Medicine, 2006
- In Vitro Demonstration of the Heavy-Atom Effect for Photodynamic TherapyJournal of the American Chemical Society, 2004
- Photodynamic therapy: a new antimicrobial approach to infectious disease?Photochemical & Photobiological Sciences, 2004
- Clinical Potential of Photodynamic Therapy in Cardiovascular DisordersAmerican Journal of Cardiovascular Drugs, 2001
- Initial results from the Sherbrooke avalanche photodiode positron tomographIEEE Transactions on Nuclear Science, 1996